Payment overview · 2025
General Payments
$97.30
5 reported records · 5 companies
Healthcare provider profile · identity verified
Catherine D Morris, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CANTON, GA · NPI 1619984820
Verified facts
What the public records show
CMS Open Payments records show Catherine D Morris, M.D. received $97.30 in general payments during 2025 across 5 reported records.
Eisai Inc. accounted for 31.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 266 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Eisai Inc. | Unresolved — no canonical attribution shown | $30.85 | 31.7% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $19.52 | 20.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.51 | 18.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.39 | 15.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.03 | 14.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $97.30 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $30.85 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 266 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
266 | 47 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1104 | 265 |
| Atorvastatin Calcium | Atorvastatin Calcium | 891 | 237 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 822 | 231 |
| Amlodipine Besylate | Amlodipine Besylate | 705 | 183 |
| Losartan Potassium | Losartan Potassium | 692 | 191 |
| Lisinopril | Lisinopril | 635 | 170 |
| Alprazolam | Alprazolam | 588 | 102 |
| Hydrochlorothiazide | Hydrochlorothiazide | 396 | 114 |
| Pantoprazole Sodium | Pantoprazole Sodium | 362 | 92 |
| Omeprazole | Omeprazole | 361 | 106 |
| Metformin Hcl | Metformin Hcl | 355 | 110 |
| Sertraline Hcl | Sertraline Hcl | 328 | 85 |
| Escitalopram Oxalate | Escitalopram Oxalate | 310 | 84 |
| Simvastatin | Simvastatin | 310 | 90 |
| Zolpidem Tartrate | Zolpidem Tartrate | 270 | 54 |
| Synthroid | Levothyroxine Sodium | 267 | 70 |
| Ozempic | Semaglutide | 266 | 47 |
| Famotidine | Famotidine | 264 | 67 |
| Potassium Chloride | Potassium Chloride | 259 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 251 | 60 |
| Lorazepam | Lorazepam | 245 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 227 | 63 |
| Trazodone Hcl | Trazodone Hcl | 224 | 57 |
| Carvedilol | Carvedilol | 215 | 60 |
| Citalopram Hbr | Citalopram Hydrobromide | 213 | 54 |
| Montelukast Sodium | Montelukast Sodium | 204 | 67 |
| Bupropion Xl | Bupropion Hcl | 195 | 60 |
| Gabapentin | Gabapentin | 183 | 46 |
| Hydralazine Hcl | Hydralazine Hcl | 167 | 42 |
| Fluoxetine Hcl | Fluoxetine Hcl | 161 | 36 |
| Metformin Hcl Er | Metformin Hcl | 149 | 37 |
| Memantine Hcl | Memantine Hcl | 147 | 23 |
| Repatha Sureclick | Evolocumab | 144 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 140 | 33 |
| Furosemide | Furosemide | 136 | 41 |
| Allopurinol | Allopurinol | 131 | 36 |
| Ezetimibe | Ezetimibe | 128 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 121 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 24 |
| Buspirone Hcl | Buspirone Hcl | 110 | 35 |
| Mirtazapine | Mirtazapine | 105 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 98 | 25 |
| Benazepril Hcl | Benazepril Hcl | 93 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 93 | 21 |
| Mounjaro | Tirzepatide | 92 | 19 |
| Atenolol | Atenolol | 90 | 23 |
| Spironolactone | Spironolactone | 90 | 22 |
| Eliquis | Apixaban | 88 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 34 |
| Donepezil Hcl | Donepezil Hcl | 75 | 13 |
| Januvia | Sitagliptin Phosphate | 75 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 18 |
| Glipizide | Glipizide | 73 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 30 |
| Warfarin Sodium | Warfarin Sodium | 70 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 68 | 20 |
| Clonazepam | Clonazepam | 66 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 66 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 63 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 14 |
| Tramadol Hcl | Tramadol Hcl | 57 | 21 |
| Valsartan | Valsartan | 57 | 15 |
| Glimepiride | Glimepiride | 56 | 20 |
| Nifedipine Er | Nifedipine | 54 | suppressed |
| Lovastatin | Lovastatin | 53 | 16 |
| Myrbetriq | Mirabegron | 50 | 14 |
| Temazepam | Temazepam | 46 | suppressed |
| Glipizide Er | Glipizide | 44 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 11 |
| Acyclovir | Acyclovir | 43 | 12 |
| Alendronate Sodium | Alendronate Sodium | 40 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | 12 |
| Pregabalin | Pregabalin | 40 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | suppressed |
| Fluconazole | Fluconazole | 35 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 33 |
| Topiramate | Topiramate | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 32 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Eszopiclone | Eszopiclone | 33 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Meloxicam | Meloxicam | 28 | 15 |
| Praluent Pen | Alirocumab | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 15 |
| Estradiol | Estradiol | 26 | 15 |
| Risperidone | Risperidone | 26 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 23 | suppressed |
| Dexamethasone | Dexamethasone | 23 | 21 |
| Amoxicillin | Amoxicillin | 22 | 17 |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 22 | 20 |
| Rabeprazole Sodium | Rabeprazole Sodium | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Prednisone | Prednisone | 20 | 17 |
| Telmisartan | Telmisartan | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Tri-Estarylla | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Wegovy | Semaglutide | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Pentasa | Mesalamine | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Unithroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $97.30 · 5 records | Eisai Inc. | AREXVY, LEQVIO, Leqembi, Ozempic, Rybelsus, SHINGRIX, WAKIX | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error